

Tools for Accessing Personalized Care

- Ensure that your doctor has experience treating prostate cancer. Consider consulting a specialist or obtaining a second opinion, so you can feel confident in your diagnosis and treatment plan.
- Ask a friend or loved to join you during key discussions with your provider, to help you process the information and to make decisions.
- Be sure to request all essential testing, <u>including biomarker testing</u>, and ask how the results may affect your prognosis and treatment options.
- Discuss ALL of the treatments available to you, including any potential side effects.
- Ask if there is a clinical trial that could be right for you.
- Share your opinions and ask questions throughout the process, so you feel empowered and informed about your care.

| | Symptoms of Advanced Prostate Cancer | | Advanced Prostate Cancer Treatment Considerations Include: |
|---|---|---|---|
| • | Urinary symptoms, such as urinary frequency, feeling of incomplete emptying | • | Biomarker test results. A patient's age, overall health, and any pre- |
| • | or weak urinary flow. Bone pain, commonly in the spine, back or pelvis. | : | existing conditions. The type, stage, and grade of prostate cancer. Potential side effects or impact on their |
| • | Heightened risk of fracture. | | lifestyle. |
| • | Blood clots and/or lower extremity swelling. | • | Patient preference. |
| | Kidney disfunction. Fatigue and/or general malaise. | | |

Glossary Terms

Biomarker Testing (molecular testing): Laboratory testing that identifies certain genes, proteins, or other molecules in a sample of tissue, blood, or other body fluid. In cancer, it may also be used to evaluate treatment or to make a prognosis.

Immunotherapy: Type of therapy that harnesses one's own immune system to help the body fight cancer, infection, and other diseases.

Microsatellite Instability (MSI): The presence of MSI may help determine a treatment plan.

Mismatch Repair Deficiency (dMMR): An inability to correct DNA replication errors, leading to an increased cancer risk.

Metastatic Castration-Resistant Prostate Cancer (mCRPC): The cancer has spread beyond the prostate, and it is resistant to treatments that lower the amount of male sex hormone in a patient's body.

PARP Inhibitors: A type of targeted treatment that inhibits the enzyme poly (ADP-ribose) polymerase.

Prostate-Specific Antigen (PSA): Protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the level of PSA in the blood.

Insist! Prostate Cancer is brought to you by the Patient Empowerment Network. It is made possible through support from Myovant Sciences, and through generous donations from people like you.



question@powerfulpatients.org

www.powerfulpatients.org



@power4patients